1 Title

2 Pre-diagnostic circulating concentrations of insulin-like growth factor-1 and risk
3 of COVID-19 mortality: results from UK Biobank

5 Authors

6 Xikang Fan^{1*}, Cheng Yin^{2*}, Jiayu Wang¹, Mingjia Yang¹, Hongxia Ma^{1,3,4},
7 Guangfu Jin^{1,3,4}, Mingyang Song^{5,6,7}, Zhibin Hu^{1,3,4}, Hongbing Shen^{1,4}, Dong
8 Hang^{1,4}

10 * Co-first authors, contributed equally.

12 Affiliations

13 ¹ Department of Epidemiology and Biostatistics, International Joint Research
14 Center on Environment and Human Health, Center for Global Health, School
15 of Public Health, Nanjing Medical University, Nanjing, China, 211166;

16 ² Department of Laboratory, Jiangning Hospital Affiliated to Nanjing Medical
17 University, Nanjing, China, 211100;

18 ³ State Key Laboratory of Reproductive Medicine, Center for Global Health,
19 Nanjing Medical University, Nanjing, China, 211166;

20 ⁴ Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment,
21 Collaborative Innovation Center for Cancer Medicine, Nanjing Medical
22 University, Nanjing, China, 211166;

23 ⁵ Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston,
24 MA, USA, 02115;

⁶ Department of Epidemiology, Harvard T.H. Chan School of Public Health,
Boston, MA, USA, 02115;

⁷ Clinical and Translational Epidemiology Unit and Division of Gastroenterology,
Massachusetts General Hospital and Harvard Medical School, Boston, MA,
USA, 02114.

30

Short title: IGF-1 and COVID-19 mortality

32

Keywords: IGF-1, COVID-19, SARS-CoV-2, coronavirus infection, mortality,
UK Biobank

35

Correspondence:

Dong Hang, PhD

Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer
Biomarkers, Prevention and Treatment, Collaborative Innovation Center for
Cancer Medicine, Center for Global Health, School of Public Health, Nanjing
Medical University, 101 Longmian Avenue, Nanjing 211166, China.

Email: hangdong@njmu.edu.cn

ORCID numbers: 0000-0001-6944-0459 (D. Hang).

44

Funding

This study was funded by National Natural Science Foundation of China
(81820108028, 81521004, and 81973127), National Key R&D Program of

48 China (2016YFC1000200 and 2017YFC0908300), and Science Foundation for
49 Excellent Young Scholars of Jiangsu (BK20190083). The funders had no role
50 in study design, data collection and analysis, decision to publish, or
51 preparation of the manuscript.

52

53 **Disclosure Summary:** The authors have nothing to disclose.

54 **Abstract**

55 **Background:** Coronavirus disease 2019 (COVID-19) deteriorates suddenly
56 primarily due to excessive inflammatory injury, and insulin-like growth factor-1
57 (IGF-1) is implicated in endocrine control of the immune system. However, the
58 effect of IGF-1 levels on COVID-19 prognosis remains unknown.

59 **Objective:** To investigate the association between circulating IGF-1
60 concentrations and mortality risk among COVID-19 patients.

61 **Design:** Prospective analysis.

62 **Setting:** UK Biobank.

63 **Participants:** 1425 COVID-19 patients who had pre-diagnostic serum IGF-1
64 measurements at baseline (2006-2010).

65 **Main outcome measures:** COVID-19 mortality (available death data updated
66 to 22 May 2020). Unconditional logistic regression was performed to estimate
67 the odds ratio (OR) and 95% confidence intervals (CIs) of mortality across the
68 IGF-1 quartiles.

69 **Results:** Among 1425 COVID-19 patients, 365 deaths occurred due to
70 COVID-19. Compared to the lowest quartile of IGF-1 concentrations, the
71 highest quartile was associated with a 37% lower risk of mortality (OR: 0.63,
72 95% CI: 0.43-0.93, P -trend=0.03). The association was stronger in women and
73 nonsmokers (both P -interaction=0.01).

74 **Conclusions:** Higher IGF-1 concentrations are associated with a lower risk of
75 COVID-19 mortality. Further studies are required to determine whether and

76 how targeting IGF-1 pathway might improve COVID-19 prognosis.

77

78 **Abbreviations**

79 COVID-19: coronavirus disease 2019; BMI: body mass index; MET, metabolic

80 equivalent; ICD: international classification of diseases; OR: odds ratio; CI:

81 confidence interval.

82 Introduction

83 An outbreak of Coronavirus Disease 2019 (COVID-19) began in December
84 2019 and has triggered a public health emergency of international concern ¹.
85 The majority of COVID-19 patients have a self-limiting infection and recover,
86 but some suffer severe symptoms and even die ². The suddenly deteriorating
87 conditions of some patients are mainly attributed to systematic inflammatory
88 injury caused by the excessive or uncontrolled activation of immune response,
89 known as the cytokine storm, leading to respiratory distress syndrome (ARDS)
90 and multiple organ failure ³.

91 Insulin-like growth factor 1 (IGF-1) belongs to the IGF family that plays a
92 critical role in diverse biological activities including cell proliferation,
93 metabolism, differentiation, and survival ⁴. Cumulative evidence also supports
94 that IGF-1 pathway can regulate the immune response via interaction with
95 various cytokines (e.g., interferons) and immune cells such as T lymphocytes,
96 macrophages, and bone marrow cells ⁵. IGF-1 may act as an important switch
97 controlling the amplitude and quality of the immune response ⁶. Of note, IGF-1
98 administration is already an approved therapy for growth failure and may
99 improve symptoms of autoimmune diseases such as type-1 diabetes and
100 multiple sclerosis ⁷. However, whether IGF-1 plays a role in COVID-19
101 prognosis remains unknown.

102 Therefore, in the current study, we used the UK Biobank resource, with
103 recently released data on COVID-19 tests and updated death records, to

104 investigate the association between pre-diagnostic serum IGF-1

105 concentrations and mortality among COVID-19 patients.

106

107 **Methods**

108 **Study Participants**

109 UK Biobank is a prospective cohort study consisting of approximately half a
110 million participants (aged 37-73 years) recruited across the UK between 2006
111 and 2010⁸. Up to 22 May 2020, among 5516 participants who had undergone
112 COVID-19 PCR tests provided by Public Health England, 1422 patients were
113 diagnosed with COVID-19. In the current analysis, we also included additional
114 150 patients who died from COVID-19 according to the National Health
115 Service death records. The patients who had no available data on serum
116 IGF-1 (n=140) or died from other causes (n=7, including colon cancer, lung
117 cancer, dementia, chronic ischaemic heart disease, and bronchopneumonia)
118 were excluded, leaving 1425 patients in the final analysis.

119

120 **Assessment of IGF-1**

121 Details about serum biomarker measurements and assay performances have
122 been described online
123 ([http://biobank.ndph.ox.ac.uk/showcase/showcase/docs/serum_biochemistry.](http://biobank.ndph.ox.ac.uk/showcase/showcase/docs/serum_biochemistry.pdf)
124 pdf). Briefly, serum concentrations of IGF-1 were measured in UK Biobank's
125 purpose-built facility using a 'one step sandwich' Chemiluminescent

126 Immunoassay method based on DiaSorin Liaison XL Analyzer (Diasorin S.p.A),
127 with a detection range of 1.3-195 nmol/L. The average coefficients of variation
128 of IGF-1 derived from internal quality control samples of known high, medium,
129 and low concentrations were 6.18%, 5.29%, and 6.03%, respectively.
130 Moreover, the assay of serum IGF-1 was registered with an external quality
131 assurance (EQA) scheme (RIQAS Immunoassay Speciality 1) to verify
132 accuracy. The EQA results showed that 100% of participated distributions
133 (n=105) were good or acceptable.

134

135 **Ascertainment of COVID-19 Mortality**

136 Dates and causes of death were obtained from death certificates held by the
137 National Health Service Information Centre (England and Wales) and the
138 National Health Service Central Register Scotland (Scotland)⁹. The outcome
139 of current study was mortality due to COVID-19 (ICD-10 U07) and available
140 death data were updated to 22 May 2020.

141

142 **Ascertainment of Covariates**

143 At baseline, participants attended one of 22 assessment centers across
144 England, Scotland, and Wales where they completed a touch-screen,
145 self-completed questionnaire. Ethnicity, smoking status, and alcohol intake
146 were self-reported. Height and body weight were measured by trained nurses
147 at baseline, and body mass index (BMI) was calculated as weight in kilograms

148 divided by height in meters squared. Townsend deprivation index was derived
149 from residence using data on car and home ownership, unemployment, and
150 household overcrowding. Physical activity was measured as total metabolic
151 equivalent task-minutes per week for all activity including walking, moderate
152 and vigorous activity.

153

154 **Statistical Analysis**

155 Because the date of COVID-19 testing did not represent the time of infection,
156 the survival time for each patient could not be accurately estimated, leading to
157 Cox regression models inapplicable in the current analysis. Therefore, we
158 analyzed the association between IGF-1 and COVID-19 mortality using
159 unconditional logistic regression models. Odds ratios (OR) and 95%
160 confidence intervals (CI) for each quartile of IGF-1 were calculated, with the
161 lowest quartile as the reference. Model 1 was adjusted for major covariates
162 including age at infection, sex, and ethnicity; Model 2 was further adjusted for
163 Townsend deprivation index, BMI, smoking status, alcohol drinking, and
164 physical activity. We also additionally adjusted for C-reactive protein in those
165 who had the inflammatory biomarker data (n=1418), and the results were
166 essentially unchanged (data not shown).

167 Stratified analyses were conducted according to the median age at
168 infection (<70, ≥70 years), sex (male, female), BMI (<30, ≥30 kg/m²), physical
169 activity (≤median, >median), and smoking status (never, ever) in the

170 fully-adjusted model. To investigate potential effect modification by these
171 stratification variables, we used a likelihood ratio test comparing the models
172 with and without interaction terms between IGF-1 concentrations and each of
173 the stratification variables.

174 Sensitivity analyses were performed by excluding participants with
175 baseline cancer or cardiovascular disease. We used SAS 9.4 for all analyses.
176 All statistical tests were two-sided, and $P < 0.05$ was defined as statistically
177 significant.

178

179 **Results**

180 Among 1425 COVID-19 patients, 365 deaths occurred due to COVID-19. The
181 median time from baseline blood draw to COVID-19 testing was 11.1 years
182 (interquartile range: 10.5-11.8 years). The distribution of IGF-1 concentrations
183 is shown in **Figure 1**, ranging from 4.79 to 46.09 nmol/L, which was similar to
184 the distribution in the whole cohort (data not shown).

185 **Table 1** summarizes the main characteristics of COVID-19 patients
186 according to quartiles of serum IGF-1 concentrations. At baseline, participants
187 with higher IGF-1 had a lower BMI and higher levels of physical activity, and
188 tended to be younger, males, and nonsmokers.

189 As shown in **Table 2**, higher IGF1 concentrations were associated with a
190 reduced risk of COVID-19 mortality in the multivariable models (Model 1, OR
191 comparing quartile 5 verse 1: 0.58, 95% CI: 0.39-0.85, P -trend=0.01). The

192 association remained stable after further adjustment for the other confounders
193 (Model 2, OR: 0.63, 95% CI: 0.43-0.93, P -trend=0.03).

194 **Figure 2** shows the forest plot results of stratified analyses. The inverse
195 associations of IGF-1 with a COVID-19 mortality were largely consistent
196 across subgroups, except for sex and smoking status. The association
197 appeared to be stronger in women and nonsmokers (both P -interaction=0.01).

198 Sensitivity analyses showed that the aforementioned associations
199 remained basically unchanged after excluding 238 individuals who had
200 baseline cancer or cardiovascular disease (**Table 3**).

201

202 Discussion

203 To the best of our knowledge, this study was the first to demonstrate an
204 inverse association between pre-diagnostic circulating levels of IGF-1 and
205 COVID-19 mortality risk among COVID-19 patients, particularly for women and
206 nonsmokers. Our findings suggest that IGF-1 might play a role in COVID-19
207 prognosis.

208 Cytokine storm has been recognized as one of the major causes of ARDS
209 and multiple organ failure in COVID-19 patients. Therefore, effectively
210 suppressing the cytokine storm is important to prevent the disease
211 deterioration and reduce COVID-19 mortality. Markedly elevated levels of
212 circulating IL-6, IL-2R, IL-10, TNF α , etc. have been detected in patients with
213 severe COVID-19^{10 11}. These cytokines are mainly produced by macrophages

214 and lymphocytes which have been implicated in cytokine storm ¹². Several
215 studies in humans and animal models have suggested an anti-inflammatory
216 effect of IGF-1. For example, there is an inverse relationship between
217 circulating IGF-1 and IL-6 levels ^{13 14}, and IGF-1/IGF binding protein-3
218 administration to severely burned patients effectively attenuated inflammatory
219 effects and reduced IL-6 levels ¹⁵. Recombinant human IGF-1 infusion into
220 ApoE-deficient mice significantly decreased macrophage infiltration by
221 downregulating IL-6 and TNF- α expression ¹⁶. In addition, recombinant human
222 IGF-1 can mediate autoimmune suppression in mouse models of autoimmune
223 disease by increasing regulatory T cells in affected tissues ⁷. However, it
224 remains uncertain whether gender and smoking status modify the role of IGF-1
225 in immune regulation, and other studies also reported that IGF-1 might exert
226 pro-inflammatory effects ^{17 18}. Future studies are necessary to clarify the
227 mechanism of IGF-1 in COVID-19 prognosis.

228 Our study has several strengths. First, UK Biobank is a well-designed
229 large cohort and are providing reliable data on COVID-19 diagnosis and
230 related deaths, allowing us to do the analysis in a timely fashion. Second,
231 biochemistry assays of IGF-1 were performed in a single dedicated central
232 laboratory by a standard, reliable method and strict quality control procedures.
233 Third, we were able to adjust for various covariates on demographic and
234 lifestyle factors.

235 Several potential limitations also need to be acknowledged. First, the

236 observational nature of this study prevents us from inferring causality. However,
237 our sensitivity analyses excluding baseline CVD and cancer supported the
238 robustness of the findings. Second, given the lack of repeated IGF-1
239 measurements, we were unable to analyze the relationship between dynamic
240 IGF-1 concentrations and COVID-19 mortality. However, we calculated the
241 intraclass correlation coefficient (ICC) between IGF1 measurements collected
242 4 years apart in a subcohort (n= 16,356). The ICC value of 0.78, consistent
243 with the previous data ¹⁹, indicates that IGF1 levels are generally stable over
244 time. Third, due to limited coverage of coronavirus testing in the UK,
245 ascertainment bias cannot be avoided. In addition, UK Biobank is not a
246 representative sample of the UK population ²⁰, limiting ability to generalize the
247 results to the whole UK or other populations.

248

249 **Conclusions**

250 The current study indicates that higher serum IGF-1 concentrations are
251 associated with a lower risk of COVID-19 mortality. Further studies are
252 warranted to validate our findings and clarify underlying mechanisms.

253

254 **Acknowledgments**

255 We are grateful to UK Biobank participants. This research has been conducted
256 using the UK Biobank resource under application number 52217.

257

258 Author Contributions

259 DH was responsible for the conception and design of the study. XF and DH
260 had full access to all the data in the study and took responsibility for the
261 integrity of the data and the accuracy of the data analysis. XF and CY did the
262 statistical analysis and drafted the manuscript. JW, MY, HM, GJ, MS, ZH, and
263 HS critically revised the manuscript for important intellectual content. All
264 authors reviewed and approved the final manuscript.

265

266 References

- 267 1. Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome
268 coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19):
269 The epidemic and the challenges. *Int J Antimicrob Agents*
270 2020;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924
- 271 2. Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and
272 mechanisms of immunopathological changes in COVID-19. *Allergy* 2020
273 doi: 10.1111/all.14364
- 274 3. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'Cytokine
275 Storm' in COVID-19. *J Infect* 2020;80(6):607-13. doi:
276 10.1016/j.jinf.2020.03.037
- 277 4. Stewart CE, Rotwein P. Growth, differentiation, and survival: multiple
278 physiological functions for insulin-like growth factors. *Physiol Rev*
279 1996;76(4):1005-26. doi: 10.1152/physrev.1996.76.4.1005
- 280 5. Skarlis C, Nezos A, Mavragani CP, et al. The role of insulin growth factors in
281 autoimmune diseases. *Annals of Research Hospitals* 2019;3
- 282 6. Smith TJ. Insulin-like growth factor-I regulation of immune function: a
283 potential therapeutic target in autoimmune diseases? *Pharmacol Rev*
284 2010;62(2):199-236. doi: 10.1124/pr.109.002469
- 285 7. Bilbao D, Luciani L, Johannesson B, et al. Insulin-like growth factor-1
286 stimulates regulatory T cells and suppresses autoimmune disease. *EMBO*
287 *Mol Med* 2014;6(11):1423-35. doi: 10.15252/emmm.201303376
- 288 8. Collins R. What makes UK Biobank special? *Lancet* 2012;379(9822):1173-4.
289 doi: 10.1016/S0140-6736(12)60404-8
- 290 9. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource
291 for identifying the causes of a wide range of complex diseases of middle
292 and old age. *PLoS Med* 2015;12(3):e1001779. doi:

10.1371/journal.pmed.1001779

10. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest* 2020;130(5):2620-29. doi: 10.1172/JCI137244

11. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5

12. Arango Duque G, Descoteaux A. Macrophage cytokines: involvement in immunity and infectious diseases. *Front Immunol* 2014;5:491. doi: 10.3389/fimmu.2014.00491

13. Rajpathak SN, McGinn AP, Strickler HD, et al. Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. *Growth Horm IGF Res* 2008;18(2):166-73. doi: 10.1016/j.ghir.2007.08.004

14. Succurro E, Andreozzi F, Sciacqua A, et al. Reciprocal association of plasma IGF-1 and interleukin-6 levels with cardiometabolic risk factors in nondiabetic subjects. *Diabetes Care* 2008;31(9):1886-8. doi: 10.2337/dc08-0553

15. Spies M, Wolf SE, Barrow RE, et al. Modulation of types I and II acute phase reactants with insulin-like growth factor-1/binding protein-3 complex in severely burned children. *Crit Care Med* 2002;30(1):83-8. doi: 10.1097/00003246-200201000-00013

16. Sukhanov S, Higashi Y, Shai SY, et al. IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. *Arterioscler Thromb Vasc Biol* 2007;27(12):2684-90. doi: 10.1161/ATVBAHA.107.156257

17. Li G, Zhou L, Zhang C, et al. Insulin-Like Growth Factor 1 Regulates Acute Inflammatory Lung Injury Mediated by Influenza Virus Infection. *Front Microbiol* 2019;10:2541. doi: 10.3389/fmicb.2019.02541

18. Wolters TLC, Netea MG, Hermus A, et al. IGF1 potentiates the pro-inflammatory response in human peripheral blood mononuclear cells via MAPK. *J Mol Endocrinol* 2017;59(2):129-39. doi: 10.1530/JME-17-0062

19. Goodman-Gruen D, Barrett-Connor E. Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. *Am J Epidemiol* 1997;145(11):970-6. doi: 10.1093/oxfordjournals.aje.a009065

20. Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. *Am J Epidemiol* 2017;186(9):1026-34. doi: 10.1093/aje/kwx246

333 **Figure Legend**

334 **Figure 1.** The distribution histogram of IGF-1 concentrations.

335 **Figure 2.** Forest plots of stratified analysis for the associations between serum

336 IGF-1 concentrations and the risk of COVID-19 mortality.

Table 1. Baseline characteristics of COVID-19 patients according to quartiles of serum IGF-1 concentrations

Characteristic	Serum IGF-1 concentrations, nmol/L			
	Q1 (4.79-17.09)	Q2 (17.11-20.78)	Q3 (20.79-24.47)	Q4 (24.47-46.09)
Participants N	356	356	357	356
Age at blood draw, mean (SD), y	60.08 (7.33)	57.83 (9.24)	56.52 (9.29)	54.51 (9.36)
Age at infection, mean (SD), y	71.26 (7.39)	69.02 (9.36)	67.64 (9.32)	65.65 (9.32)
Female, No. (%)	180 (50.56)	168 (47.19)	168 (47.06)	150 (42.13)
White race, No. (%)	315 (88.48)	314 (88.20)	299 (83.75)	312 (87.64)
Body mass index, mean (SD), kg/m ²	29.88 (6.01)	29.20 (5.59)	28.52 (5.31)	27.90 (4.78)
Physical activity, mean (SD), MET-hours/w	37.08 (39.46)	42.98 (44.06)	43.73 (39.08)	47.96 (49.10)
Townsend deprivation index, No. (%)				
Low	102 (28.65)	104 (29.21)	140 (39.22)	134 (37.64)
Middle	118 (33.15)	135 (37.92)	115 (32.21)	107 (30.06)
High	136 (38.20)	117 (32.87)	102 (28.57)	115 (32.30)
Smoking status, No. (%)				
Never	139 (39.04)	167 (46.91)	176 (49.30)	186 (52.25)
Previous	167 (46.91)	146 (41.01)	134 (37.54)	124 (34.83)
Current	45 (12.64)	40 (11.24)	44 (12.32)	45 (12.64)
Alcohol consumption, No. (%)				
Daily to three times a week	119 (33.43)	134 (37.64)	109 (30.53)	119 (33.43)
Twice a week to once a month	114 (32.02)	140 (39.33)	142 (39.78)	150 (42.13)
Never or special occasions only	120 (33.71)	81 (22.75)	104 (29.13)	87 (24.44)

Abbreviations: MET, metabolic equivalent.

Table 2. Association between serum IGF-1 concentrations and COVID-19 mortality

	Quartile of serum IGF-1 concentrations, OR (95% CI)				<i>P</i> -trend
	Q1 (4.79-17.09)	Q2 (17.11-20.78)	Q3 (20.79-24.47)	Q4 (24.47-46.09)	
No. of cases	122	95	86	62	
Model 1	ref	0.77 (0.55-1.09)	0.77 (0.54-1.09)	0.58 (0.39-0.85)	0.01
Model 2	ref	0.82 (0.58-1.17)	0.84 (0.59-1.21)	0.63 (0.43-0.93)	0.03

Model 1: adjusted for age at infection, sex, race. Model 2: adjusted for model 1 plus Townsend deprivation index, body mass index, smoking status, alcohol drinking, and physical activity. *P*-trend was based on the median value of each quartile of serum IGF-1 concentrations as a continuous variable in the models. Abbreviations: OR, odds ratio; CI, confidence interval; ref, reference.

Table 3. Association between serum IGF-1 concentrations and COVID-19 mortality after excluding participants with baseline cancer or cardiovascular disease (n=238)

	Quartile of serum IGF-1 concentrations, OR (95% CI)				<i>P</i> -trend
	Q1 (4.79-17.14)	Q2 (17.17-20.79)	Q3 (20.79-24.46)	Q4 (24.46-46.09)	
No. of cases	96	76	70	41	
Model 1	ref	0.83 (0.57-1.23)	0.86 (0.58-1.27)	0.52 (0.33-0.81)	0.01
Model 2	ref	0.88 (0.59-1.31)	0.95 (0.63-1.42)	0.58 (0.37-0.93)	0.047

Model 1: adjusted for age at infection, sex, race. Model 2: adjusted for model 1 plus Townsend deprivation index, body mass index, smoking status, alcohol drinking, and physical activity. *P*-trend was based on the median value of each quartile of serum IGF-1 concentrations as a continuous variable in the models. Abbreviations: OR, odds ratio; CI, confidence interval; ref, reference.